Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Change in Taxes (2020 - 2024)

BioNexus Gene Lab's Change in Taxes history spans 5 years, with the latest figure at -$87057.0 for Q3 2024.

  • For Q3 2024, Change in Taxes fell 6482.48% year-over-year to -$87057.0; the TTM value through Sep 2024 reached -$53591.0, up 70.41%, while the annual FY2023 figure was -$44648.0, N/A changed from the prior year.
  • Change in Taxes for Q3 2024 was -$87057.0 at BioNexus Gene Lab, down from $57018.0 in the prior quarter.
  • Across five years, Change in Taxes topped out at $107779.0 in Q4 2020 and bottomed at -$153209.0 in Q4 2022.
  • The 5-year median for Change in Taxes is -$3540.0 (2023), against an average of $688.16.
  • The largest annual shift saw Change in Taxes skyrocketed 339.28% in 2021 before it tumbled 6482.48% in 2024.
  • A 5-year view of Change in Taxes shows it stood at $107779.0 in 2020, then plummeted by 122.26% to -$23994.0 in 2021, then plummeted by 538.53% to -$153209.0 in 2022, then soared by 89.07% to -$16744.0 in 2023, then plummeted by 419.93% to -$87057.0 in 2024.
  • Per Business Quant, the three most recent readings for BGLC's Change in Taxes are -$87057.0 (Q3 2024), $57018.0 (Q2 2024), and -$6808.0 (Q1 2024).